Fate Therapeutics, Inc. (NASDAQ:FATE) insider Daniel D. Shoemaker sold 13,225 shares of the business’s stock in a transaction on Monday, October 16th. The stock was sold at an average price of $3.87, for a total transaction of $51,180.75. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Shares of Fate Therapeutics, Inc. (NASDAQ:FATE) opened at 4.11 on Friday. Fate Therapeutics, Inc. has a 52 week low of $1.80 and a 52 week high of $5.68. The stock has a 50 day moving average of $4.10 and a 200-day moving average of $3.67. The firm’s market cap is $170.22 million.

Fate Therapeutics (NASDAQ:FATE) last issued its quarterly earnings results on Monday, August 14th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.01. Fate Therapeutics had a negative net margin of 887.68% and a negative return on equity of 67.01%. The firm had revenue of $1.03 million during the quarter, compared to the consensus estimate of $1.02 million. Equities research analysts expect that Fate Therapeutics, Inc. will post ($0.97) earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another site, it was copied illegally and reposted in violation of United States and international trademark and copyright laws. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2017/10/20/fate-therapeutics-inc-fate-insider-sells-51180-75-in-stock.html.

A number of equities analysts have commented on FATE shares. Zacks Investment Research lowered shares of Fate Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday. ValuEngine upgraded shares of Fate Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, August 29th. Leerink Swann restated an “outperform” rating and issued a $7.00 target price on shares of Fate Therapeutics in a research note on Friday, September 8th. Finally, HC Wainwright restated a “buy” rating and issued a $7.00 target price on shares of Fate Therapeutics in a research note on Thursday, October 12th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $6.79.

Institutional investors have recently modified their holdings of the business. Wells Fargo & Company MN lifted its holdings in shares of Fate Therapeutics by 926.7% during the 1st quarter. Wells Fargo & Company MN now owns 281,111 shares of the biopharmaceutical company’s stock worth $1,279,000 after acquiring an additional 253,732 shares during the period. Morgan Stanley lifted its holdings in shares of Fate Therapeutics by 9.8% during the 1st quarter. Morgan Stanley now owns 611,646 shares of the biopharmaceutical company’s stock worth $2,783,000 after acquiring an additional 54,615 shares during the period. Neuberger Berman Group LLC bought a new position in shares of Fate Therapeutics during the 1st quarter worth about $312,000. Driehaus Capital Management LLC bought a new position in shares of Fate Therapeutics during the 1st quarter worth about $145,000. Finally, KCG Holdings Inc. lifted its holdings in shares of Fate Therapeutics by 7.8% during the 1st quarter. KCG Holdings Inc. now owns 24,480 shares of the biopharmaceutical company’s stock worth $111,000 after acquiring an additional 1,764 shares during the period. 64.27% of the stock is owned by hedge funds and other institutional investors.

Fate Therapeutics Company Profile

Fate Therapeutics, Inc (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity.

Receive News & Stock Ratings for Fate Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics Inc. and related stocks with our FREE daily email newsletter.